Mangalam Drugs Defaults on Loans Worth ₹15.57 Crore to Banks

BANKINGFINANCE
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Mangalam Drugs Defaults on Loans Worth ₹15.57 Crore to Banks

Mangalam Drugs & Organics Ltd reported defaults on cash credit loans to Bank of Maharashtra and Bank of Baroda, totaling ₹15.57 crore. The company has failed to pay interest and principal since October 2025, highlighting financial stress.

Mangalam Drugs Defaults on ₹15.57 Crore Loans

Mangalam Drugs & Organics Ltd has reported defaults on its cash credit loan accounts with Bank of Maharashtra and Bank of Baroda. The total overdue amount stands at ₹15.57 crore, with defaults persisting since October 2025.

Reader Takeaway: Company defaults on significant loan amounts, signaling financial strain; management is arranging payments.

What just happened

Mangalam Drugs & Organics Ltd informed the stock exchanges about its failure to meet interest and principal payments on loan accounts. The defaults involve ₹9.51 crore with Bank of Maharashtra and ₹6.06 crore with Bank of Baroda.

Why this matters

These defaults, which have been ongoing since October 2025, indicate significant financial stress and liquidity issues for the company. This development raises concerns about the company's ability to manage its short-term obligations and its overall financial health.

The backstory

The company had previously intimated the banks on February 16, 2026, regarding these defaults. This subsequent disclosure highlights that the situation has not yet been resolved, with dues remaining outstanding for nearly ten months.

What changes now

Investors should be concerned about the sustained default. The company management has stated they are making arrangements to clear the dues soon. Continued non-payment could lead to further actions by the banks and regulatory scrutiny.

Risks to watch

The primary risk is the prolonged financial strain, which could impact operations, creditworthiness, and potentially lead to more severe actions from lenders. Investors need to watch for signs of financial restructuring or asset sales.

Peer comparison

Information on specific loan defaults for peers in the pharmaceuticals sector is not readily available from this filing. However, consistent defaults generally place a company at a disadvantage compared to financially stable peers.

Context metrics (time-bound)

The defaults on Bank of Maharashtra loan (account 60383561246) and Bank of Baroda loan (account 04170500000243) started on October 17, 2025, and October 20, 2025, respectively. As of August 16, 2026, the total overdue amount is ₹15.57 crore (₹1,557.27 lakh).

What to track next

Investors should closely monitor future company announcements for updates on loan repayments, any potential asset sales, or capital infusion plans to resolve these outstanding dues.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.